Simplifying the Complex Cancer Research Reimagined
A Powerhouse CRO in a Small Package, Uniquely Structured for Immunotherapy Trials
OncoBay is a boutique CRO, offering comprehensive, custom-curated solutions to biopharma and biotech companies who are ready to advance their immuno-oncology assets from concept to clinic.
Your trial will benefit from transparent project pricing and the responsive oversight of a dedicated team who will be serving you every step of the way.
Enhancing your Team with IO Expertise
The immuno-oncology (IO) development space is evolving, and OncoBay Clinical can help you ensure your IO asset meets clinical development goals both today and in the future. Specializing in immuno-oncology clinical trials, our company boasts a respected team of executive leaders with over 100 years of oncology operations experience.
Every team member is experienced in IO, and because we are a smaller firm, you are not separated from critical experience by deep layers of organizational infrastructure. You have access to a responsive and expert team that is dedicated to your clinical trial from start to finish.
The development of immunotherapy assets is a particularly complex process.
As a subsidiary of Moffitt Cancer Center, an internationally known leader in cancer treatment and research, OncoBay can leverage the unrivaled support of Moffitt’s top scientific advisors to help you design the most efficient plan for developing your asset.
OncoBay also partners with Moffitt’s integrated cell-manufacturing capabilities, resulting in “vein-to-vein” control for your clinical trial.
OncoBay Clinical expertly manages clinical trials to maximize results and to minimize time and costs.
Native to the OncoBay framework are comprehensive technological solutions that—when coupled with both our advanced clinical oversight and our integrated data review, reporting, and analysis—ensures the accuracy, efficiency, and quality of your trial.
With customized strategic and tactical solutions, OncoBay is specifically designed to provide ongoing and transparent risk analysis and mitigation to immuno-oncology trials.
With our prodigious site network, OncoBay is working to assure that patients receive the treatments they need in a manner most befitting: from physicians they know and trust, surrounded by the people they love, in the communities where they live.
Once three entities – OncoBay Clinical, Clinscience, and Exom Group s.r.l – now we stand as one, bringing forth a symphony of expertise and seamless operations. To celebrate our unity, we re-brand under the banner of Kapadi, and embark on a new chapter of exceptional service in oncology clinical research.
Kapadi is not just a name; it's a testament to our fusion. It signifies the our standing as a global CRO powerhouse committed to accelerating groundbreaking cancer therapies that uplift patients worldwide. From conceptualizing studies, navigating regulations, and analyzing data, we provide a comprehensive array of services designed to empower your oncology clinical trials.
